Crossmark

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Crossref DOI link: https://doi.org/10.1186/s12885-023-10676-x

Published Online: 2023-03-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Ziyi

Hao, Xuezhi

Wang, Qi

Yang, Ke

Li, Junling

Xing, Puyuan
License Information

Text and Data Mining valid from 2023-03-04

Version of Record valid from 2023-03-04
More Information

Article History

Received: 18 November 2022

Accepted: 24 February 2023

First Online: 4 March 2023

Declarations

:

: This study was approved by the Ethics Committee of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS and Peking Union Medical College (approval No. 21/352–3023). This study was done in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. Informed consent was waived by the Ethics Committee of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS and Peking Union Medical College due to the retrospective nature of review.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below